Emulatebio
5 known investors
Emulate develops Organ-Chip technology, including 30+ organ models such as liver, brain, and other human tissue chips, used for human-based preclinical drug safety and toxicity testing. It serves pharmaceutical and biomedical researchers as a human-relevant alternative to animal testing, and works closely with the FDA including acceptance into the ISTAND pilot program.
BiotechDeep TechHealthtech
Investors Β· 5
Non-dilutive funding Β· 1 SBIR/STTR award
Federal grants β no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $150K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts β non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Emulatebio do?
- Emulate develops Organ-Chip technology, including 30+ organ models such as liver, brain, and other human tissue chips, used for human-based preclinical drug safety and toxicity testing. It serves pharmaceutical and biomedical researchers as a human-relevant alternative to animal testing, and works closely with the FDA including acceptance into the ISTAND pilot program.
- Who are Emulatebio's investors?
- Emulatebio's investors include +ND Capital, Alwyn Capital, Stray Dog Capital, OS Fund, Starlight Ventures.